Semaglutide vs tirzepatide: Which leads to more weight loss?

In a head-to-head trial of specific weekly injection doses, tirzepatide led to greater average weight loss than semaglutide in adults with obesity without diabetes. Results vary. The finding applies to the products, doses, and people studied. It does not mean every person will lose more weight with tirzepatide.

Your response can depend on the dose you tolerate, how long you use treatment, other health conditions, and daily habits. Side effects or missed doses may also affect your treatment plan. A drug that causes more weight loss on average may not be the best fit for your health or needs.

Semaglutide has a longer history of clinical use. That can be part of the discussion, but it does not make it automatically safer or better for every person.

Trial findings for approved products should not be treated as proof of results with compounded preparations. Compounded medications are prepared by a licensed pharmacy for one patient and are not FDA-approved. A physician licensed in your state can help weigh the evidence against your personal risks and goals.